SCHEMBL20155997

SCHEMBL20155997

CCc1cccc(-c2ncsn2)c1OC

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.32
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31
TUBB4B P68371 1/20 0.31
TUBB3 Q13509 1/20 0.31
TUBB2A Q13885 1/20 0.31
TUBB8 Q3ZCM7 1/20 0.31
TUBA3E Q6PEY2 1/20 0.31
TUBA1A Q71U36 1/20 0.31
TUBA1C Q9BQE3 1/20 0.31
TUBB6 Q9BUF5 1/20 0.31
TUBB2B Q9BVA1 1/20 0.31
TUBB1 Q9H4B7 1/20 0.31
GABRA1 P14867 2/20 0.31
GABRB2 P47870 2/20 0.31
KDM4E B2RXH2 2/20 0.31
HPGD P15428 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24026538 0.81 CTSA (0.36) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL17198731 0.80 CLK4 (0.39) DRD2GABRA1GABRB2KDM4EMAPT
SCHEMBL20150095 0.77 TSHR (0.33) GABRA1GABRB2HPGDL3MBTL1POLB
SCHEMBL20230841 0.76 CASP6 (0.33) DRD2GABRA1GABRB2KDM4EHPGD
SCHEMBL20230880 0.75 BRD4 (0.33) DRD2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL21091002 0.75 TYK2 (0.39) DRD2
SCHEMBL20230857 0.73 TUBB4A (0.36) DRD2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL17198791 0.73 SMN1; SMN2 (0.44) KDM4EHPGDMAPTHTTSMN1; SMN2
SCHEMBL21091022 0.72 TYK2 (0.41) KDM4EHPGDMAPTSMN1; SMN2ALDH1A1
SCHEMBL15698670 0.72 JAK2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DRD2 4650/4885TUBB4A 2425/4885TUBB 1669/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DRD2 4650/4885TUBB4A 2425/4885TUBB 1669/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 DRD2 4650/4885TUBB4A 2425/4885TUBB 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.